Skip to content
Biodatica
Start free

Institut Curie

Paris

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

9mo agoTrial registeredSep 25, 2025Source filing (opens the source filing in a new tab)

Momentum

51no change

Momentum 51 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,325 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Apr 5, 2024

    Triple Negative Breast Neoplasms · TERMINATED · sponsor: Institut Curie · "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer

    ClinicalTrials.gov · NCT06067061 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Oct 30, 2020

    Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary · ACTIVE_NOT_RECRUITING · sponsor: Institut Curie · LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

    ClinicalTrials.gov · NCT04446962 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources